Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC)
Current Oncology Reports · 2026
DOI: 10.1007/s11912-026-01751-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology Reports, 2026. Verfasst von Abhinav Vyas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology and Hematology, Loma Linda University, Loma Linda, CA, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose of Review With the approvals of various targeted therapies including tyrosine kinase inhibitors to antibody–drug conjugates, the treatment landscape of patients with EGFR-mutant non-small cell lung cancer has drastically improved. The use of EGFR-targeted therapies has shifted to include not only advanced/ metastatic disease but also to early-stage non-small cell lung cancer. Recent Findings Novel therapy options have sought to address the need for effective agents against acquired resistance mechanisms in EGFR mutations. Further, the role of tyrosine kinase inhibitors against EGFR mutation in the perioperative setting has been most recently evaluated. With early outcomes, clinicians are met with the need to guide patients through various treatment regimens, and mature survival results are anticipated for several key trials. Of import, the growing focus on personalized treatment options based on outcomes, quality-of-life, toxicity, tolerability, and various disease-related factors warrants consideration. Summary This review comprehensively describes frontline and subsequent-line therapy options for patients with early stage, unresectable/ locally advanced, and advanced/ metastatic stages of EGFR-mutant non-small cell lung cancer, including unprecedented therapeutic agents.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology and Hematology, Loma Linda University, Loma Linda, CA, USA.
- O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA.
- Department of General Oncology, Division of Cancer, Medicine, MD Anderson Cancer Center, Houston, TX, USA.
- Medical Oncology, Henry Ford Health, Detroit, MI, USA.
- Division of Hematology/Medical Oncology, Oregon Health & Science University, Portland, OR, USA. thawani@ohsu.edu.
- O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, USA. aakashdesai@uabmc.edu.
ORCID-Profile: Rajat Thawani, Aakash Desai
Zitieren
APA
Vyas, A., Jeon, W. J., Alhushki, S., Singhi, E., Rous, F. A., Thawani, R., & Desai, A. (2026). Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC). Current Oncology Reports. https://doi.org/10.1007/s11912-026-01751-0
Vancouver
Vyas A, Jeon WJ, Alhushki S, Singhi E, Rous FA, Thawani R, et al. Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC). Current Oncology Reports. 2026. doi:10.1007/s11912-026-01751-0
BibTeX
@article{Vyas2026,
author = {Vyas, Abhinav and Jeon, Won Jin and Alhushki, Sanad and Singhi, Eric and Rous, Fawzi Abu and Thawani, Rajat and Desai, Aakash},
title = {Updates in the Management of EGFR-Mutated Non-small Cell Lung Cancer (NSCLC)},
journal = {Current Oncology Reports},
year = {2026},
doi = {10.1007/s11912-026-01751-0}
}
EUVIMED